
    
      This is a multiple-dose, randomized, double-blind (with respect to telaglenastat and
      placebo), placebo- and positive controlled, 3 way crossover thorough QT (TQT) study in
      healthy adult subjects.

      On Day 1 of Period 1, subjects will be randomized to 1 of 6 treatment sequences.

      In Treatments A and B, subjects will receive the assigned treatment on Day 1 through the
      morning of Day 4. In Treatment C, subjects will receive a single-dose administration of
      moxifloxacin in the morning of Day 4. Cardiodynamic readings will be collected for 24 hours
      on Days 1 and 4. Plasma PK samples will be collected prior to dosing (for Treatments A and B
      or Hour 0 for Treatment C) and up to 24 hours on Days 1 and 4 of all treatments.
    
  